资讯

Nature14 年
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other hematological malignancies. However, its impact on the immune system has ...
Nature6 年
Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor
Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...